<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087058</url>
  </required_header>
  <id_info>
    <org_study_id>RLY5016-206p</org_study_id>
    <secondary_id>2016-002785-31</secondary_id>
    <nct_id>NCT03087058</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic &amp; Safety of Patiromer in Children &amp; Adolescents (2-&lt;18 Yrs) With Chronic Kidney Disease and Hyperkalemia</brief_title>
  <acronym>EMERALD</acronym>
  <official_title>A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to &lt; 18 Years of Age With Chronic Kidney Disease and Hyperkalemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vifor Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the change in serum (blood) potassium levels from&#xD;
      start of treatment to Day 14, when patiromer is administered at different doses, once daily,&#xD;
      in children 2 - &lt; 18 years of age with chronic kidney disease (CKD) and hyperkalemia (too&#xD;
      much potassium in the blood). Another purpose of the study is to evaluate the safety and&#xD;
      tolerability of patiromer in children 2 - &lt; 18 years of age with CKD and hyperkalemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 54 subjects, 2 - &lt; 18 years of age with CKD (estimated glomerular filtration rate&#xD;
      [eGFR] &lt; 90 mL/min/1.73 m2 ) and hyperkalemia (two potassium measurements of 5.1 to &lt; 6.5&#xD;
      mEq/L performed on separate days) will be enrolled in this open-label, multiple-dose, Phase 2&#xD;
      study.&#xD;
&#xD;
      The study will include two treatment phases: Pharmacodynamic (PD; drug effect on potassium) /&#xD;
      Dose Finding Phase consisting of the initial 14-day dose finding period followed by an up to&#xD;
      5.5-month Long-Term Treatment Phase for a total study participation duration for individual&#xD;
      subjects of up to 6.5 months (includes a 2 week follow up period).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum potassium (K+) levels from Baseline to Day 14</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>Changes in serum potassium levels will be summarized by starting dose and age group using descriptive statistics. Descriptive statistics include mean, standard deviation, and 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with serum K+ levels in the range of 3.8 - 5.0 mEq/L at Day 14 (Initial PD / Dose Finding Phase)</measure>
    <time_frame>Day 14</time_frame>
    <description>Proportions and associated exact 95% confidence interval will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with serum K+ levels in the range of 3.8 - 5.0 mEq/L by visit at any time through Month 6 (Long-Term Treatment Phase)</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Proportions and associated 95% confidence interval will be presented.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patiromer for age 12 - &lt; 18 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patiromer for age 6 - &lt; 12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patiromer for age 2 - &lt; 6 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer</intervention_name>
    <description>4.2 g/day, 8.4 g/day and 16.8 g/day</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Veltassa</other_name>
    <other_name>RLY5016 for Oral Suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer</intervention_name>
    <description>2 g/day, 4 g/day and 8 g/day</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Veltassa</other_name>
    <other_name>RLY5016 for Oral Suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer</intervention_name>
    <description>1 g/day, 2 g/day and 4 g/day</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Veltassa</other_name>
    <other_name>RLY5016 for Oral Suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written assent (when applicable) and written informed consent by a legally authorized&#xD;
             representative provided prior to participation in the study&#xD;
&#xD;
          -  Age 2 - &lt;18 years old&#xD;
&#xD;
          -  CKD defined by the estimated glomerular filtration rate (eGFR) &lt;90 mL/min/1.73m2,&#xD;
             including renal transplant subjects, based on local creatinine measurement at&#xD;
             screening&#xD;
&#xD;
          -  Two potassium measurements of 5.1 to &lt; 6.5 mEq/L performed on separate days&#xD;
&#xD;
          -  In the opinion of the study doctor, is expected to require treatment for hyperkalemia&#xD;
             for at least 6 month&#xD;
&#xD;
          -  If taking any renin-angiotensin-aldosterone system inhibitors (RAASi) beta blockers or&#xD;
             diuretic medications, must be on a stable dose for at least 28 days prior to Screening&#xD;
&#xD;
          -  Negative pregnancy test in females of child-bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pseudohyperkalemia due to hemolysis or to abnormally high numbers of platelets&#xD;
             (&gt;500,000/mm3), leukocytes (&gt;70,000/mm3), or erythrocytes (hematocrit &gt;55%) at&#xD;
             Screening based on results obtained locally&#xD;
&#xD;
          -  Evidence of potassium-related electrocardiogram (ECG) changes at Screening&#xD;
&#xD;
          -  Any of the following kidney conditions: maintenance hemodialysis or peritoneal&#xD;
             dialysis, renal artery stenosis, and acute kidney injury or a history of acute renal&#xD;
             insufficiency in the past 3 months&#xD;
&#xD;
          -  Severe disorder of stomach or intestines including surgery that could affect&#xD;
             gastrointestinal transit of the drug&#xD;
&#xD;
          -  Increased liver enzymes (ALT, AST &gt; 3 times upper limit of normal) at Screening&#xD;
&#xD;
          -  Active cancer, currently on cancer treatment or history of cancer in the past 2 years&#xD;
             (except for non-melanoma skin cancer)&#xD;
&#xD;
          -  Heart or liver transplant, or anticipated need for transplant during the study&#xD;
             treatment period including a scheduled kidney transplant recipient. (Note: patients&#xD;
             currently on a kidney transplant wait list are not excluded unless there is an&#xD;
             identified donor).&#xD;
&#xD;
          -  Alcohol abuse or substance use disorder within 1 year of Screening&#xD;
&#xD;
          -  Subjects currently being treated with or having taken any one of the following&#xD;
             medications (includes resins) in the 7 days prior to Screening: sodium or calcium&#xD;
             polystyrene sulfonate, drospirenone&#xD;
&#xD;
          -  Use of certain medications that can affect blood potassium levels if doses have not&#xD;
             been stable for at least 14 days prior to Screening or if doses are anticipated to&#xD;
             change during the 14-day PD / Dose Finding Phase&#xD;
&#xD;
          -  Use of investigational product within 30 days of screening or within 5 half-lives,&#xD;
             whichever is longer&#xD;
&#xD;
          -  Known hypersensitivity to patiromer or its components&#xD;
&#xD;
          -  In the opinion of the Investigator, any medical condition, uncontrolled systemic&#xD;
             disease, or serious intercurrent illness that would significantly decrease study&#xD;
             compliance or jeopardize the safety of the subject or potentially affect the quality&#xD;
             of the data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Udo-Michael Göhring</last_name>
    <role>Study Director</role>
    <affiliation>Vifor Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site 1107</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94394</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1101</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1103</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1102</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1105</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1108</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1104</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1109</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1113</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1106</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1401</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1902</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3915</name>
      <address>
        <city>Tbilisi</city>
        <zip>0121</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3913</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3911</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3912</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3914</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4312</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4313</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4311</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investiagor Site 4314</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5401</name>
      <address>
        <city>Bialystok</city>
        <zip>15-274</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5404</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5406</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5402</name>
      <address>
        <city>Lodz</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5403</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5405</name>
      <address>
        <city>Warsaw</city>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7906</name>
      <address>
        <city>Dnipropetrovs'k</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7903</name>
      <address>
        <city>Kharkiv</city>
        <zip>61075</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7904</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of Hyperkalemia</keyword>
  <keyword>Hyperkalemia</keyword>
  <keyword>Potassium</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

